<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04045028</url>
  </required_header>
  <id_info>
    <org_study_id>GO41036</org_study_id>
    <nct_id>NCT04045028</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD), and Preliminary Activity of Tiragolumab in Participants With Relapsed or Refractory Multiple Myeloma or With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma</brief_title>
  <official_title>A Phase Ia/Ib Open-Label, Multicenter Study Evaluating the Safety and Pharmacokinetics of Tiragolumab as a Single Agent and in Combination With Atezolizumab and/or Daratumumab in Patients With Relapsed or Refractory Multiple Myeloma, and as a Single Agent and in Combination With Rituximab in Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Genentech, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Genentech, Inc.</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase I open-label, multicenter study designed to evaluate the safety,&#xD;
      tolerability, pharmacokinetics, pharmacodynamics, and preliminary activity of tiragolumab&#xD;
      administered as a single agent or in combination with atezolizumab and/or daratumumab or&#xD;
      rituximab in participants with relapsed or refractory (R/R) multiple myeloma (MM) or R/R&#xD;
      non-Hodgkin lymphoma (NHL).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In the Phase Ia part of the study, tiragolumab is administered as a single agent in&#xD;
      participants with R/R MM or R/R NHL.&#xD;
&#xD;
      In the Phase Ib part of the study, tiragolumab is administered in combination with&#xD;
      atezolizumab and/or daratumumab in participants with R/R MM or with rituximab in participants&#xD;
      with R/R NHL.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 22, 2019</start_date>
  <completion_date type="Anticipated">December 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">September 1, 2023</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants With Adverse Events</measure>
    <time_frame>Through study completion, an average of 1 year</time_frame>
    <description>Determined according to the NCI CTCAE Version 5.0</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serum Concentration of Tiragolumab</measure>
    <time_frame>Cycles 1, 2, 3, 4, 8, 12, 16, 17 and then every 8 cycles (each cycle is 21 days) and at Treatment Discontinuation Visit (up to 2 years)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Concentration of Atezolizumab</measure>
    <time_frame>Cycles 1, 2, 3, 4, 8, 12, 16, 17 and then every 8 cycles (each cycle is 21 days) and at Treatment Discontinuation Visit (up to 2 years)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate (ORR) for R/R MM</measure>
    <time_frame>Through study completion, an average of 1 year</time_frame>
    <description>Proportion of participants with a best overall response of stringent complete response (sCR), complete response (CR), very good partial response (VGPR) or partial response (PR), as defined by the International Myeloma Working Group (IMWG) criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ORR for R/R NHL</measure>
    <time_frame>Through study completion, an average of 1 year</time_frame>
    <description>Proportion of participants with a CR or PR on two consecutive occasions &gt;/= 4 weeks apart, according to the Lugano classification</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Anti-Drug Antibodies (ADAs) to Tiragolumab</measure>
    <time_frame>Cycles 1, 2, 4, 8, 12, 16, 17 and then every 8 cycles (each cycle is 21 days) and at Treatment Discontinuation Visit (up to 2 years)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With ADAs to Atezolizumab</measure>
    <time_frame>Cycles 1, 2, 4, 8, 12, 16, 17 and then every 8 cycles (each cycle is 21 days) and at Treatment Discontinuation Visit (up to 2 years)</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Multiple Myeloma</condition>
  <condition>Non-Hodgkin Lymphoma</condition>
  <condition>B-Cell Lymphoma</condition>
  <arm_group>
    <arm_group_label>Arm A: Tiragolumab R/R MM</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with relapsed or refractory (R/R) Multiple Myeloma (MM) will receive a single dose of 600 mg tiragolumab by intravenous (IV) infusion on Day 1 of each 21-day cycle (Q3W).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B: Tiragolumab R/R NHL</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with relapsed or refractory (R/R) non-Hodgkin Lymphoma (NHL) will receive a single dose of 600 mg tiragolumab by IV infusion Q3W.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm C: Tiragolumab + Daratumumab R/R MM</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with R/R MM will receive 600 mg tiragolumab Q3W + daratumumab by subcutaneous (SC) injection.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm D: Tiragolumab + Rituximab R/R NHL</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with R/R NHL will receive 600 mg tiragolumab Q3W + rituximab by IV infusion and SC injection (optional).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm E: Tiragolumab + Atezolizumab + Daratumumab R/R MM</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with R/R MM will receive 600 mg tiragolumab Q3W + atezolizumab by IV infusion Q3W + daratumumab by SC injection.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tiragolumab</intervention_name>
    <description>Administered by IV infusion at a fixed dose of 600 mg on Day 1 of each 21-day cycle (Q3W)</description>
    <arm_group_label>Arm A: Tiragolumab R/R MM</arm_group_label>
    <arm_group_label>Arm B: Tiragolumab R/R NHL</arm_group_label>
    <arm_group_label>Arm C: Tiragolumab + Daratumumab R/R MM</arm_group_label>
    <arm_group_label>Arm D: Tiragolumab + Rituximab R/R NHL</arm_group_label>
    <arm_group_label>Arm E: Tiragolumab + Atezolizumab + Daratumumab R/R MM</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Daratumumab/rHuPH20</intervention_name>
    <description>Administered by SC injection 1800 mg/30,000 U rHuPH20 weekly for a total of 6 doses, then every 3 weeks for a total of 16 doses (first dose given at Week 7), then every 4 weeks from Week 55 onward until disease progression</description>
    <arm_group_label>Arm C: Tiragolumab + Daratumumab R/R MM</arm_group_label>
    <arm_group_label>Arm E: Tiragolumab + Atezolizumab + Daratumumab R/R MM</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rituximab</intervention_name>
    <description>Administered for a total of 8 doses. Rituximab will be administered by IV infusion for the first dose at a dose of 375 mg/m^2. After administration of at least one full infusion of IV rituximab, the SC formulation of rituximab (rituximab and rHuPH20) may be used for the remaining doses per institutional guidelines. SC rituximab will be administered at a dose of 1400 mg rituximab/23400 U rHuPH20 once weekly (QW).</description>
    <arm_group_label>Arm D: Tiragolumab + Rituximab R/R NHL</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atezolizumab</intervention_name>
    <description>Administered by IV infusion at a fixed dose of 1200 mg Q3W</description>
    <arm_group_label>Arm E: Tiragolumab + Atezolizumab + Daratumumab R/R MM</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        General Inclusion Criteria (All Participants):&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1&#xD;
&#xD;
          -  Life expectancy of &gt;/= 12 weeks&#xD;
&#xD;
        Inclusion Criteria Specific to Arms A, C and E (R/R MM):&#xD;
&#xD;
          -  Arm A only: Must have R/R MM for which no established therapy for MM is appropriate&#xD;
             and available or be intolerant to those established therapies&#xD;
&#xD;
          -  Arms C and E only: Participants with R/R MM who have received at least 3 prior lines&#xD;
             of therapy.&#xD;
&#xD;
          -  Measurable disease defined by laboratory test results.&#xD;
&#xD;
        Inclusion Criteria Specific to Arms B and D (R/R NHL):&#xD;
&#xD;
          -  Participants with histologically confirmed B-cell NHL who have relapsed or failed to&#xD;
             respond to at least two prior systemic treatment regimens and for which no suitable&#xD;
             therapy of curative intent or higher priority exists.&#xD;
&#xD;
          -  Must have at least one bi-dimensionally measurable lesion.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        General Exclusion Criteria (All Participants):&#xD;
&#xD;
          -  Any anti-cancer therapy, whether investigational or approved, including chemotherapy,&#xD;
             monoclonal antibody, radioimmunoconjugate, antibody-drug conjugate, hormonal therapy,&#xD;
             and/or radiotherapy, within 4 weeks or 5 half-lives of the drug, whichever is shorter,&#xD;
             prior to initiation of study treatment&#xD;
&#xD;
          -  Prior treatment with any anti-TIGIT agent&#xD;
&#xD;
          -  Prior treatment with chimeric antigen receptor-T (CAR-T) therapy within 12 weeks&#xD;
             before first study drug administration&#xD;
&#xD;
          -  Autologous Stem-Cell Transplantation (ASCT) within 100 days prior to first study drug&#xD;
             administration&#xD;
&#xD;
          -  Active or history of autoimmune disease or immune deficiency&#xD;
&#xD;
          -  Known active bacterial, viral (including SARS-CoV-2), fungal, mycobacterial,&#xD;
             parasitic, or other infection at study enrollment, or any major episode of infection&#xD;
             within 4 weeks prior to first study drug administration&#xD;
&#xD;
        Exclusion Criteria Specific to Arms A, C and E (R/R MM):&#xD;
&#xD;
          -  Primary or secondary plasma cell leukemia&#xD;
&#xD;
          -  Current or history of CNS involvement by MM&#xD;
&#xD;
        Exclusion Criteria Specific to Arms B and D (R/R NHL):&#xD;
&#xD;
          -  Uncontrolled hypercalcemia or symptomatic hypercalcemia requiring continued use of&#xD;
             bisphosphonate therapy or denosumab&#xD;
&#xD;
          -  Current or history of CNS lymphoma&#xD;
&#xD;
          -  Current eligibility for ASCT&#xD;
&#xD;
        Other protocol defined inclusion/exclusion criteria could apply&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Hoffmann-La Roche</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Reference Study ID Number: GO41036 www.roche.com/about_roche/roche_worldwide.htm</last_name>
    <phone>888-662-6728 (U.S. and Canada)</phone>
    <email>global-roche-genentech-trials@gene.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Colorado Blood Cancer Institute (CBCI) at Presbyterian/ St. Luke's Medical Center</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80218</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Emory Clinic</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Maryland</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Washington University</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63128</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Oncology Hematology Care, Inc.; Oncology Hematology Care, Inc.</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45236</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania; School of Medicine</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>SCRI</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Virginia Cancer Specialists (Fairfax) - USOR</name>
      <address>
        <city>Fairfax</city>
        <state>Virginia</state>
        <zip>22031</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Samsung Medical Center; Nephrology Department</name>
      <address>
        <city>Seoul</city>
        <zip>06351</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital; Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>110-744</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Seoul St.Mary's Hospital; Medical Oncology</name>
      <address>
        <city>Seoul</city>
        <zip>137-807</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Asan Medical Center; Internal Dept / Gastorenterology</name>
      <address>
        <city>Seoul</city>
        <zip>138-736</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>July 22, 2019</study_first_submitted>
  <study_first_submitted_qc>August 2, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 5, 2019</study_first_posted>
  <last_update_submitted>October 14, 2021</last_update_submitted>
  <last_update_submitted_qc>October 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Atezolizumab</mesh_term>
    <mesh_term>Daratumumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Qualified researchers may request access to individual patient level data through the clinical study data request platform (www.vivli.org). Further details on Roche's criteria for eligible studies are available here (https://vivli.org/ourmember/roche/). For further details on Roche's Global Policy on the Sharing of Clinical Information and how to request access to related clinical study documents, see here (https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm).</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

